medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2022, Number 3

<< Back Next >>

Rev ADM 2022; 79 (3)

Side effects after SARS-CoV-2 Sinovac® immunization, applied to dental students aged 20-30 years.

Álvarez RA, Muela CD, Domínguez TNI, Corral AMM, Montes CLO, Nevárez RA, Gil RBG

Language: Spanish
References: 21
Page: 129-135
PDF size: 206.70 Kb.


ABSTRACT

The FAERS, FDA Adverse Event Reporting System, has reported certain adverse reactions to vaccines that may occur uncommonly, with neurological symptoms being the most frequent of this group, manifesting as dizziness, pain headache, neuralgia, muscle spasms, myalgia, and paraesthesia. CoronaVac-Sinovac® is a chemically inactive whole virus vaccine for COVID-19, created from African green monkey kidney cells that have been inoculated with the SARS-CoV-2 CZ02 strain. 90 young volunteer students between 20 and 30 years old received the immunization schedule in two doses 50 days apart, in the present study the symptoms secondary to the first and second dose were observed, using an instrument for collecting information regarding the health status before and after the administration of the first and second dose of vaccination, focused on side effects. The results showed as the most frequent symptoms: Insomnia, tiredness, joint pain, drowsiness and localized pain in the puncture area, the latter being the most frequent, a close association was also observed with sex, age, and body mass index. Studies with a larger number of observed populations are necessary to establish conclusive results.


REFERENCES

  1. Chilamakuri R, Agarwal S. COVID-19: characteristics and therapeutics. Cells. 2021; 10 (2): 206. Available from: https://pubmed.ncbi.nlm.nih.gov/33494237

  2. Bayram A, Demirbakan H, Günel Karadeniz P, Erdogan M, Kocer I. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021; 93 (9): 5560-5567.

  3. Finsterer J, Scorza FA. SARS-CoV-2 vaccines are not free of neurological side effects. Acta Neurol Scand. 2021; 144 (1): 109-110. Available in: https://pubmed.ncbi.nlm.nih.gov/34002379

  4. Goss AL, Samudralwar RD, Das RR, Nath A. ANA Investigates: Neurological Complications of COVID-19 vaccines. Ann Neurol. 2021; 89 (5): 856-857.

  5. Ranzani OT, Hitchings MDT, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021; 374: n2015.

  6. Pérez-Conforme HG, Rodrìguez-Parrales DH. Eficacia y efectos secundarios de la vacuna Sinovac contra el covid-19 en el Ecuador. Rev científica Dominio las Ciencias. 2021; 7 (5): 16-33.

  7. Gaus D. COVID-19: vacunas. Práctica Fam Rural. 2021; 6 (1).

  8. Galván-Casas C, Català A, Muñoz-Santos C. Vacunas frente a SARS-CoV-2 y piel. Actas Dermosifiliogr. 2021; 112 (9): 828-836.

  9. Escobar-Muciño E, Gamboa-Pérez A. Antivirales, terapias y candidatos a la vacuna contra el virus emergente del síndrome respiratorio agudo grave (SARS-CoV-2). Alianzas y Tendencias - BUAP. 2020; 5 (19): 26-42.

  10. Hernández FJ. Vacunas y vacunación contra el COVID-19. Rev Mutis [Internet]. 2020; 10 (2): 5-9. Available in: https://revistas.utadeo.edu.co/index.php/mutis/article/view/1737

  11. Weinstein C, Andresen M, Corrales R, Gallardo J, Noriega V, Sánchez E. Avances y desafíos en las vacunas el para control de la pandemia por COVID-19. ARS MEDICA Rev Ciencias Médicas. 2021; 46 (2): 3-5.

  12. Teixeira GS. Comparación de 9 vacunas contra la COVID-19. Medscape. 2021; 19-23. Disponible en: https://espanol.medscape.com/verarticulo/5906665_2

  13. Hungerford D, Cunliffe NA. Efectividad en el mundo real de las vacunas covid-19. BMJ. 2021; 1 (1): 374.

  14. Díaz Ortega JL. Guía técnica para la aplicación de la vacuna Sinovac "SARS-CoV-2 (Células Vero) inactivada", contra el virus SARS-CoV-2 [Internet]. Ciudad de México. Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2021/03/GTApp_Sinovac_050321.pdf

  15. Chuaychoosakoon C, Parinyakhup W, Tanutit P, Maliwankul K, Klabklay P. Shoulder injury related to Sinovac COVID-19 vaccine: a case report. Ann Med Surg. 2021; 68: 102622.

  16. Torres RC. Covid-19. Variante delta y efectividad de vacunas y efectividad de vacunas [Internet]. Instituto Belisario Domínguez, Senado de la República. Ciudad de México; 2021. Disponible en: http://bibliodigitalibd.senado.gob.mx/handle/123456789/5404

  17. Martín De Francisco AL. Vacunas SARS-COV2 marzo 2021. Nefrol al día [Internet]. 2021; 1-7. Disponible en: www.nefrologiaaldia.org/es

  18. Organisation Mondiale de la Santé. Recommandations provisoires pour l'utilisation du vaccin anti-COVID-19 inactivé, CoronaVac, développé par Sinovac. 2021.

  19. Lopez ME, Espinoza J, Dabanch J, Cruz R. Emergencia de variante Delta-B.1.617.2. Su impacto potencial en la evolución de la pandemia por SARS-CoV-2. Boletín Micológico. 2021; 36.

  20. Orellana J, Guerrero Sotelo R. La variante SARS-CoV-2 ómicron. Rev ADM. 2022; 79: 28-31.

  21. Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2022; 43 (1): 3-40.




2020     |     www.medigraphic.com